Trial
NCT03713944
Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Nasser Hanna
Collaborators
Genentech, Inc.
Condition
NSCLC Stage IV
Intervention
Carboplatin
Why stopped
Extreme toxicity, thromboembolic events
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-03-01